The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
Open accessAbstract
// Christine Böger 1 , Hans-Michael Behrens 1 , Micaela Mathiak 1 , Sandra Krüger 1 , Holger Kalthoff 2 , Christoph Röcken 1 1 Department of Pathology, Christian-Albrechts-University, Kiel, Germany 2 Department of Experimental Cancer Research, Christian-Albrechts-University, Kiel, Germany Correspondence to: Christoph Röcken, e-mail: christoph.roecken@uksh.de Keywords: programmed death-1, predictive biomarker, immune therapy, pembrolizumab Received: February 03, 2016 Accepted: March 02, 2016 Published: March 18, 2016 ABSTRACT Targeting the PD-1/PD-L1 immune checkpoint signaling is a novel promising treatment strategy in several tumor entities, and it is suggested that PD-L1/PD-1 expression is predictive for a PD-1/PD-L1 checkpoint inhibitor treatment response. We investigated the expression of PD-L1 and PD-1 by immunohistochemistry in a large and well characterized gastric cancer (GC) cohort of Caucasian patients, consisting of 465 GC samples and 15 corresponding liver metastases. Staining results were correlated with clinico-pathological characteristics and survival. PD-L1 expression was found in tumor cells of 140 GCs (30.1%) and 9 liver metastases (60%) respectively in immune cells of 411 GCs (88.4%) and 11 liver metastases (73.3%). PD-1 was expressed in tumor infiltrating lymphocytes in 250 GCs (53.8%) and in 11 liver metastases (73.3%). PD-L1 expression was significantly more prevalent in men, GCs of the proximal stomach, unclassified, papillary, Her2/neu-positive, Epstein-Barr-virus-positive, microsatellite instable, and PIK3CA -mutated GCs. A high PD-L1/PD-1 expression was associated with a significantly better patient outcome, and PD-L1 turned out to be an independent survival prognosticator. The correlation of PD-L1/PD-1 expression with distinct clinico-pathological patient characteristics may serve as a surrogate marker of PD-L1-positive GCs and may direct the use of immune checkpoint treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
LAURÉN, P. (1965) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/apm.1965.64.1.31 · Cited by 6,133
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Chemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Wang, K., Yuen, S. T., Xu, J., Lee, S. P., Yan, H. H. N., Shi, S. T., Siu, H. C., Deng, S., Chu, K. M., Law, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2983 · Cited by 1,045
Discovering the False Discovery Rate
Benjamini, Y. (2010) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2010.00746.x · Cited by 629
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Chemotherapy for advanced gastric cancer
Wagner, A. D., Unverzagt, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J., & Fleig, W. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub3 · Cited by 472
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
Lin, S. J., Gagnon-Bartsch, J. A., Tan, I. B., Earle, S., Ruff, L., Pettinger, K., Ylstra, B., van Grieken, N., Rha, S. Y., Chung, H. C., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308252 · Cited by 229
Pembrolizumab: First Global Approval
Poole, R. M. (2014) · Drugs · doi:10.1007/s40265-014-0314-5 · Cited by 184
Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
Qing, Y., Li, Q., Ren, T., Xia, W., Peng, Y., Liu, G. L., Luo, H., Yang, Y., Dai, X. Y., Zhou, S.-F., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s75152 · Cited by 179
Mathiak, M., Warneke, V. S., Behrens, H., Haag, J., Böger, C., Krüger, S., & Röcken, C. (2015) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000264 · Cited by 152
Self-citationEto, S., Yoshikawa, K., Nishi, M., Higashijima, J., Tokunaga, T., Nakao, T., Kashihara, H., Takasu, C., Iwata, T., & Shimada, M. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0519-7 · Cited by 142
Hou, J., Yu, Z., Xiang, R., Li, C., Wang, L., Chen, S., Li, Q., Chen, M., & Wang, L. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.03.005 · Cited by 137
Zhang, L., Qiu, M., Jin, Y., Ji, J., Li, B., Wang, X., Yan, S., Xu, R., & Yang, D. (2015) · PubMed · Cited by 97
Genomic assays for Epstein–Barr virus-positive gastric adenocarcinoma
Gulley, M. L. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.93 · Cited by 71
MET in gastric cancer – discarding a 10% cutoff rule
Metzger, M., Behrens, H., Böger, C., Haag, J., Krüger, S., & Röcken, C. (2015) · Histopathology · doi:10.1111/his.12745 · Cited by 64
Self-citationAnti program death-1/anti program death-ligand 1 in digestive cancers
Guillebon, É. D., Roussille, P., Frouin, E., & Tougeron, D. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i8.95 · Cited by 56
Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints
Alsina, M., Moehler, M. H., Hierro, C., Guardeño, R., & Tabernero, J. M. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0421-1 · Cited by 42
The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism
Jiang, D., Xu, Y., Li, F., Xu, B., & Zhang, X. (2014) · Medical Oncology · doi:10.1007/s12032-014-0268-1 · Cited by 23
Li, H., Sun, Y., Chen, D., Zhao, H., Zhao, M., Zhu, X., Ke, C., Zhang, G., Jiang, C., Zhang, L., et al. (2015) · Scientific Reports · doi:10.1038/srep15712 · Cited by 20
Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort
Röcken, C., Behrens, H., Böger, C., & Krüger, S. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202980 · Cited by 19
Self-citation
Cited by
Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00386 · Cited by 305
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Gu, L., Chen, M., Guo, D., Zhu, H., Zhang, W., Pan, J., Zhong, X., Li, X., Qian, H., & Wang, X. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182692 · Cited by 280
IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma
Moon, J. W., Kong, S.-K., Kim, B. S., Kim, H. J., Lim, H., Noh, K., Kim, Y., Choi, J.-W., Lee, J.-H., & Kim, Y.-S. (2017) · Scientific Reports · doi:10.1038/s41598-017-18132-0 · Cited by 162
Metadata
- Authors
- Böger, C., Behrens, H.-M., Mathiak, M., Krüger, S., Kalthoff, H., & Röcken, C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-03-18
- Volume
- 7
- Issue
- 17
- Pages
- 24269-24283
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2300582328
- Cited by
- 287
- References
- 28
- FWCI
- 19.16
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.